0B68 Kim, Lyndon J. - Thomas Jefferson University - Thomas Jefferson University
Dr. Kim

Lyndon J. Kim, MD

Contact Dr. Kim

900 Walnut Street
Suite 200
Philadelphia, PA 19107

(215) 955-7000

Most Recent Peer-reviewed Publications

  1. A phase 2 trial of verubulin for recurrent glioblastoma: A prospective study by the brain tumor investigational consortium (BTIC)
  2. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme
  3. Chemoirradiation for Glioblastoma Multiforme: The National Cancer Institute Experience
  4. Pulmonary metastases in patients with recurrent, treatment-resistant meningioma: Prognosis and identification by 111indium-octreotide imaging
  5. Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas
  6. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas
  7. A phase I trial of enzastaurin in patients with recurrent gliomas
  8. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma
  9. Erratum: Cytotoxic chemotherapeutic management of newly diagnosed glio 1045 blastoma multiforme (Journal of Neuro-Oncology (2008) vol. 89 (339-357) 10.1007/s11060-008-9615-4)
  10. Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme
  11. A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors
  12. Chemotherapeutic options for primary brain tumors
  13. Neoplastic meningitis.
  14. Lipid-associated sialoprotein in the cerebrospinal fluid: Association with brain malignancies
  15. White-matter abnormalities in unirradiated patients cured of primary central nervous system lymphoma
  16. Concurrent chemotherapy and radiotherapy in patients with brain tumors
  17. Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors
  18. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants
  19. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas